Five things for pharma marketers to know: Wednesday, June 29, 2016



1. The FDA approved Gilead Sciences' Epclusa, the first treatment for hepatitis C that spans all genotypes of the virus. The new drug is priced at $74,760 for 12 weeks of treatment. (Bloomberg)

2. An FDA advisory panel voted 12-to-11 that Jardiance, a diabetes drug manufactured by Eli Lilly and Boehringer Ingelheim, should be allowed to claim it reduces the risk of cardiovascular death. The FDA is not required to follow the panel's recommendations, but often does. (Reuters)

3. Novartis has agreed to a licensing deal with biotech Xencor for early-stage blood cancer treatments. The deal could be worth up to $2.4 billion. (Investor's Business Daily)

4. The FDA named Dr. Richard Pazdur as the acting director of the agency's Oncology Center of Excellence, or OCE. The center was created as part of Vice President Joe Biden's Moonshot Initiative.

5. McKesson plans to form a health-information technology joint venture with Change Healthcare Holdings, part of Blackstone Group. The new company will combine McKesson's technology business with Change Healthcare Holdings. McKesson will own 70% of the company. (WSJ)

Correction: An earlier version of this article misstated that Dr. Richard Pazdur is the head of the FDA's Oncology Center of Excellence. He is the agency's acting director.